Possibilities of secondary prevention of cardiovascular complications: Focus at combination of acetylsalicylic acid with magnesium hydroxide

1. Росстат. Данные на 2022 год. Доступ: https://rosstat.gov.ru/folder/12781 (дата обращения – 01.08.2025). (Federal State Statistics Service (Russia) data for 2022. URL: https://rosstat.gov.ru/folder/12781 (date of access – 01.08.2025) (In Russ.)).

2. World Health Organization. Cardiovascular diseases (CVDs). 31 July 2025. URL: https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds) (date of access – 01.08.2025).

3. GBD 2016 Stroke Collaborators. Global, regional, and national burden of stroke, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):439–58.

PMID: 30871944. PMCID: PMC6494974. https://doi.org/10.1016/S1474-4422(19)30034-1

4. Здравоохранение в России. 2019: Стат. сб. Росстат. М. 2019; 170 с. (Healthcare in Russia. 2019: Statistical Collection. Federal State Statistics Service (Russia). Moscow. 2019; 170 pp. (In Russ.)).

5. Стаховская Л.В., Клочихина О.А., Богатырева М.Д., Коваленко В.В. Эпидемиология инсульта в России по результатам территориально-популяционного регистра (2009–2010). Журнал неврологии и психиатрии им. С.С. Корсакова. 2013;113(5):4–10. (Stakhovskaya LV, Klochikhina OA, Bogatyreva MD, Kovalenko VV. Epidemiology of stroke in Russia based on the results of the territorial-population registry (2009–2010). Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova = S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(5):4–10 (In Russ.)). EDN: QAWZFV.

6. Стаховская Л.В., Клочихина О.А., Богатырева М.Д., Чугунова С.А. Анализ эпидемиологических показателей повторных инсультов в регионах Российской Федерации (по итогам территориально-популяционного регистра 2009–2014 гг.). Consilium Medicum. 2016;18(9):8–11 (Stakhovskaya LV, Klochikhina OA, Bogatyreva MD, Chugunova SA. Analysis of epidemiological indicators of recurrent strokes in the regions of the Russian Federation (based on the results of the territorial-population register 2009–2014). Consilium Medicum. 2016;18(9):8–11 (In Russ.)). EDN: XYBMLD.

7. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A et al.; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720–826.

PMID: 37622654. https://doi.org/10.1093/eurheartj/ehad191

8. Клинические рекомендации. Острый инфаркт миокарда с подъемом сегмента ST электрокардиограммы. Общероссийская общественная организация «Российское кардиологическое общество», Ассоциация сердечно-сосудистых хирургов России, общероссийская общественная организация «Российское общество скорой медицинской помощи», Российское научное общество специалистов по рентгенэндоваскулярной диагностике и лечению. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 157_5. Доступ: https://cr.minzdrav.gov.ru/view-cr/157_5 (дата обращения – 01.08.2025). (Clinical guidelines. Acute myocardial infarction with ST-segment elevation of the electrocardiogram. Russian Society of Cardiology, Association of Cardiovascular Surgeons of Russia, Russian Society of Emergency Medical Care, Russian Scientific Society of Specialists in Roentgen-endovascular Diagnostics and Treatment. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 157_5. URL: https://cr.minzdrav.gov.ru/view-cr/157_5 (date of access – 01.08.2025) (In Russ.)).

9. Клинические рекомендации. Ишемический инсульт и транзиторная ишемическая атака. Всероссийское общество неврологов, Национальная ассоциация по борьбе с инсультом, Ассоциация нейрохирургов России, Межрегиональная общественная организация «Объединение нейроанестезиологов и нейрореаниматологов», общероссийская общественная организация «Союз реабилитологов России». Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 814_1. Доступ: https://cr.minzdrav.gov.ru/view-cr/814_1 (дата обращения – 01.08.2025). (Clinical guidelines. Ischemic stroke and transient ischemic attack. All-Russian Society of Neurology, National Association for Combating Stroke, Association of Neurosurgeons of Russia, Association of Neuroanesthesiologists and Neuroreanimatologists, Union of Rehabilitologists of Russia. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 814_1. URL: https://cr.minzdrav.gov.ru/view-cr/814_1 (date of access – 01.08.2025) (In Russ.)).

10. Клинические рекомендации. Стабильная ишемическая болезнь сердца. Ассоциация сердечно-сосудистых хирургов России, общероссийская общественная организация «Российское кардиологическое общество», автономная некоммерческая организация «Национальное общество по изучению атеросклероза», некоммерческое партнерство «Национальное общество по атеротромбозу», общероссийская общественная организация содействия развитию лучевой диагностики и терапии «Российское общество рентгенологов и радиологов», Российское научное общество специалистов по рентгенэндоваскулярной диагностике и лечению, Российское общество кардиосоматической реабилитации и вторичной профилактики (РосОКР), Российская ассоциация специалистов ультразвуковой диагностики в медицине. Рубрикатор клинических рекомендаций Минздрава России. 2024. ID: 155_2. Доступ: https://cr.minzdrav.gov.ru/view-cr/155_2 (дата обращения – 01.08.2025). (Clinical guidelines. Stable ischemic heart disease. Russian Society of Cardiology, National Society for the Study of Atherosclerosis, National Society for Atherothrombosis, Association of Cardiovascular Surgeons of Russia, Russian Society of Cardiosomatic Rehabilitation and Secondary Prevention, Russian Society of Radiologists, Russian Association of Ultrasound Diagnostics in Medicine, Russian Scientific Society of Endovascular Therapies. Rubricator of clinical guidelines of the Ministry of Healthcare of Russia. 2024. ID: 155_2. URL: https://cr.minzdrav.gov.ru/view-cr/155_2 (date of access – 01.08.2025) (In Russ.)).

11. Marquis-Gravel G, Stebbins A, Wruck LM, Roe MT, Effron MB, Hammill BG et al. Age and aspirin dosing in secondary prevention of atherosclerotic cardiovascular disease. J Am Heart Assoc. 2024;13(4):e026921.

PMID: 38348779. PMCID: PMC11010083. https://doi.org/10.1161/JAHA.122.026921

12. Jones WS, Mulder H, Wruck LM, Pencina MJ, Kripalani S, Munoz D et al.; ADAPTABLE Team. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med. 2021;384(21):1981–90.

PMID: 33999548. PMCID: PMC9908069. https://doi.org/10.1056/NEJMoa2102137

13. Pareek M, Kristensen SD, Grove EL. Cardiovascular events after discontinuation of low-dose aspirin. J Thorac Dis. 2018;10(1):75–78.

PMID: 29600025. PMCID: PMC5863118. https://doi.org/10.21037/jtd.2017.12.48

14. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982;69(6):1366–72.

PMID: 7045161. PMCID: PMC370209. https://doi.org/10.1172/jci110576

15. Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: A meta-analysis of randomised trials. Lancet Gastroenterol Hepatol. 2018;3(4):231–41.

PMID: 29475806. PMCID: PMC5842491. https://doi.org/10.1016/S2468-1253(18)30037-2

16. Shechter M, Merz CN, Paul-Labrador M, Meisel SR, Rude RK, Molloy MD et al. Beneficial antithrombotic effects of the association of pharmacological oral magnesium therapy with aspirin in coronary heart disease patients. Magnes Res. 2000;13(4):275–84. PMID: 11153897.

17. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению лекарственного препарата Фазостабил. РУ: ЛП-003790 от 17.10.2022. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b6bf0bbf-af57-4d53-aebc-47f967fd554a (дата обращения – 01.08.2025). (State Register of Medicines of the Ministry of Healthcare of Russia. Instructions for medical use of the medicinal product Fazostabil. Registration certificate: ЛП-003790 dated 17.10.2022. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=b6bf0bbf-af57-4d53-aebc-47f967fd554a (date of access – 01.08.2025) (In Russ.)).

18. Antiplatelet Trialists’ Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists’ Collaboration. Br Med J (Clin Res Ed). 1988;296(6618):320–31. PMID: 3125883. PMCID: PMC2544833.

19. Hennekens CH. Update on aspirin in the treatment and prevention of cardiovascular disease. Am J Manag Care. 2002;8(22 Suppl):S691–700. PMID: 12512736.

20. Hirsh J, Dalen JE, Fuster V, Harker LB, Patrono C, Roth G. Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. Chest. 1995;108(4 Suppl):247S–257S.

PMID: 7555180. https://doi.org/10.1378/chest.108.4_supplement.247s

21. Mayr FB, Jilma B. Current developments in anti-platelet therapy. Wien Med Wochenschr. 2006;156(17–18):472–80.

PMID: 17041802. https://doi.org/10.1007/s10354-006-0330-5

22. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86.

PMID: 11786451. PMCID: PMC64503. https://doi.org/10.1136/bmj.324.7329.71. Erratum in: BMJ. 2002;324(7330):141.

23. Antithrombotic Trialists’ (ATT) Collaboration; Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R et al. Aspirin in the primary and secondary prevention of vascular disease: Collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373(9678):1849–60.

PMID: 19482214. PMCID: PMC2715005. https://doi.org/10.1016/S0140-6736(09)60503-1

24. Berger JS, Brown DL, Becker RC. Low-dose aspirin in patients with stable cardiovascular disease: A meta-analysis. Am J Med. 2008;121(1):43–49.

PMID: 18187072. https://doi.org/10.1016/j.amjmed.2007.10.002

25. Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22):2373–83.

PMID: 16319386. https://doi.org/10.1056/NEJMra052717

26. Berkowitz SD, Bauersachs RM, Szarek M, Nehler MR, Debus ES, Patel MR et al. Prevention of arterial and venous thrombotic events in symptomatic peripheral arterial disease patients after lower extremity revascularization in the VOYAGER PAD trial: Dual anticoagulant/antiplatelet regimen vs antiplatelet therapy alone. J Thromb Haemost. 2022;20(5):1193–205.

PMID: 35170216. PMCID: PMC9314576. https://doi.org/10.1111/jth.15673

27. Miilunpohja S, Jyrkka J, Karkkainen JM, Kastarinen H, Heikkinen M, Paajanen H et al. Discontinuing low-dose acetylsalicylic acid after gastrointestinal bleeding is associated with increased mortality. Scand J Gastroenterol. 2022;57(5):618–24.

PMID: 35041575. https://doi.org/10.1080/00365521.2022.2026461

28. Collaborative overview of randomised trials of antiplatelet therapy – I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists’ Collaboration. BMJ. 1994;308(6921):81–106.

PMID: 8298418; PMCID: PMC2539220. Erratum in: BMJ 1994;308(6943):1540.

29. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet. 1996;348(9038):1329–39.

PMID: 8918275. https://doi.org/10.1016/s0140-6736(96)09457-3

30. Shechter M, Merz CN, Paul-Labrador M, Meisel SR, Rude RK, Molloy MD et al. Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am J Cardiol. 1999;84(2):152–56.

PMID: 10426331. https://doi.org/10.1016/s0002-9149(99)00225-8

31. Щедеркина И.О., Колтунов И.Е., Лившиц М.И., Петряйкина Е.Е., Витковская И.П., Кессель А.Е. с соавт. Инсульт и цереброваскулярная патология у детей и подростков. Руководство для врачей. М.: ГЭОТАР-Медиа. 2022; 448с. (Shchederkina IO, Koltunov IE, Livshits MI, Petryaikina EE, Vitkovskaya IP, Kessel AE et al. Stroke and cerebrovascular pathology in children and adolescents. Guide for doctors. Moscow: GEOTAR-Media. 2021; 448 pp. (In Russ.)).

EDN: WQVYUF. ISBN: 978-5-9704-6316-1. https://doi.org/10.33029/9704-6316-1-SCP-2022-1-448

32. Федеральное руководство по детской неврологии. Под ред. профессора Гузевой В.И. 2-е изд., доп. и перераб. СПб.: ООО «Валетудо». 2023; с. 379–430. (Federal guide to child neurology. Ed. by professor Guzeva VI. 2nd edition, supplemented and revised. Saint Petersburg: Valetudo LLS. 2023; pp. 379–430 (In Russ.)).

ISBN: 978-5-6050110-1-9.

33. Ferriero DM, Fullerton HJ, Bernard TJ, Billinghurst L, Daniels SR, DeBaun MR et al.; American Heart Association Stroke Council and Council on Cardiovascular and Stroke Nursing. Management of stroke in neonates and children: A Scientific Statement from the American Heart Association/American Stroke Association. Stroke. 2019;50(3):e51–e96.

PMID: 30686119. https://doi.org/10.1161/STR.0000000000000183

34. Medley TL, Miteff C, Andrews I, Ware T, Cheung M, Monagle P, Mandelstam S et al. Australian clinical consensus guideline: The diagnosis and acute management of childhood stroke. Int J Stroke. 2019;14(1):94–106

PMID: 30284961. https://doi.org/10.1177/1747493018799958

35. Barrett KM, Brott TG. Stroke caused by extracranial disease. Circ Res. 2017;120(3):496–501.

PMID: 28154099. https://doi.org/10.1161/CIRCRESAHA.117.310138

36. Monagle P, Chan AKC, Goldenberg NA, Ichord RN, Journeycake JM, Nowak-Göttl U, Vesely SK. Antithrombotic therapy in neonates and children: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012 Feb;141(2 Suppl):e737S–e801S.

PMID: 22315277. PMCID: PMC3278066. https://doi.org/10.1378/chest.11-2308. Erratum in: Chest. 2014;146(6):1694. Dosage error in article text. Erratum in: Chest. 2014;146(5):1422.

37. Strater R, Kurnik K, Heller C, Schobess R, Luigs P, Nowak-Gottl U. Aspirin versus low-dose low-molecular-weight heparin: Antithrombotic therapy in pediatric ischemic stroke patients: A prospective follow-up study. Stroke. 2001;32(11):2554–58.

PMID: 11692016. https://doi.org/10.1161/hs1101.097379

38. Sagar K, Smyth MR. A comparative bioavailability study of different aspirin formulations using on-line multidimensional chromatography. J Pharm Biomed Anal. 1999;21(2):383–92.

PMID: 10703994. https://doi.org/10.1016/s0731-7085(99)00177-6

39. Рафальский В.В., Крикова А.В. Клиническая фармакология ацетилсалициловой кислоты и особенности лекарственных форм – ключ к эффективному и безопасному применению для профилактики тромбозов. Медицинский совет. 2016;(5):26–33. (Rafalskiy VV, Krikova AV. Clinical pharmacology of acetylsalicylic acid and features of dosage forms – the key to effective and safe use for thrombosis prevention. Meditsinskiy sovet = Medical Council. 2016;(5):26–33 (In Russ.)).

EDN: ZGSDIJ. https://doi.org/10.21518/2079-701X-2016-05-26-33

40. Haastrup PF, Gronlykke T, Jarbol DE. Enteric coating can lead to reduced antiplatelet effect of low-dose acetylsalicylic acid. Basic Clin Pharmacol Toxicol. 2015;116(3):212–15.

PMID: 25469781. https://doi.org/10.1111/bcpt.12362

41. Rocca B, Fox KAA, Ajjan RA, Andreotti F, Baigent C, Collet JP et al. Antithrombotic therapy and body mass: An expert position paper of the ESC Working Group on Thrombosis. Eur Heart J. 2018;39(19):1672–86f.

PMID: 29509886. https://doi.org/10.1093/eurheartj/ehy066